Back to top
more

Gilead Sciences (GILD)

(Real Time Quote from BATS)

$88.84 USD

88.84
906,353

-0.16 (-0.18%)

Updated Oct 28, 2024 12:04 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Sweta Jaiswal, FRM headshot

Ride Out the Coronavirus Mayhem With These ETF Areas

by Sweta Jaiswal, FRM

We discuss some ETF areas that investors can choose to invest for a smoother sail during the coronavirus pandemic.

Gilead Sciences (GILD) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

by Zacks Equity Research

Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sweta Killa headshot

Healthcare ETFs Looks Strong Ahead of Q1 Earnings

by Sweta Killa

The healthcare sector has been on a tear driven by potential vaccines and treatments for COVID-19.

Biotech Stock Roundup: ALXN, MRNA Up on Coronavirus Treatment Updates, & More

by Zacks Equity Research

The biotech sector is in focus with pipeline updates from companies evaluating treatments for the novel COVID-19.

Sweta Jaiswal, FRM headshot

Biotech ETFs Gaining on Progress in Coronavirus Treatment

by Sweta Jaiswal, FRM

The race to introduce vaccine and treatment for coronavirus is opening up opportunities, making the biotech sector a prospective space for investments.

Sweta Killa headshot

Coronavirus Makes Biotech ETFs Red Hot

by Sweta Killa

The biotech space of the broader healthcare sector is currently the hottest of all segments buoyed by the COVID-19 pandemic.

The Zacks Analyst Blog Highlights: Alphabet, Gilead Sciences, Starbucks, Tesla and Intuit

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Alphabet, Gilead Sciences, Starbucks, Tesla and Intuit

Sanghamitra Saha headshot

4 Top Sectors of Last Week & Their Winning ETFs

by Sanghamitra Saha

These sectors topped last week and beat the broader market in a sweeping move.

Sweta Killa headshot

5 Best Sector ETFs Halfway Through April

by Sweta Killa

Given the positive developments, almost every corner of the equity world are experiencing a huge rally. Below, we have highlighted ETFs from five different segments that are leading the way in mid April.

Sweta Killa headshot

Biotech ETF (BBH) Hits New 52-Week High

by Sweta Killa

This biotech ETF hits a new 52-week high. Are more gains in store for this ETF?

Stock Market News for Apr 20, 2020

by Zacks Equity Research

U.S. stocks surged on Friday, thanks to investor optimism over a possible cure to the deadly coronavirus and President Donald Trump's plans to gradually reopen U.S. economy.

Biogen (BIIB) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Investor focus is likely to be on the impact of the coronavirus outbreak on Biogen's (BIIB) performance when it reports first-quarter results.

Gilead (GILD) in Focus: Stock Moves 9.7% Higher

by Zacks Equity Research

Gilead (GILD) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.

Ritujay Ghosh headshot

Gilead Increases Enrollment Target, Pharma Rally Continues

by Ritujay Ghosh

Substantial progress has been made over the past few weeks with pharmaceutical companies speeding up development of coronavirus vaccines.

Sanghamitra Saha headshot

5 Best Leveraged ETF Areas of Last Week

by Sanghamitra Saha

If investors can identify the trending investing area amid all the coronavirus chaos, they can easily take a leveraged position on that and beat the broader market.

Sheraz Mian headshot

Earnings Scorecard and Top Stock Reports for Alphabet, Gilead & Starbucks

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Alphabet (GOOGL), Gilead Sciences (GILD) and Starbucks (SBUX).

Mark Vickery headshot

Markets Up on COVID-19 Treatment Data

by Mark Vickery

Remsdesivir, a daily infusion treatment from Gilead Sciences (GILD) that has so far shown positive results in a phase-3 study at the University of Chicago Medicine.

Futures Up on Coronavirus Treatment Data

by Zacks Equity Research

Futures Up on Coronavirus Treatment Data

Gilead's (GILD) Coronavirus Drug Shows Promise, Shares Gain

by Zacks Equity Research

Treatment with Gilead's (GILD) experimental antiviral, remdesivir, shows rapid recoveries in fever and respiratory symptoms in COVID-19 patients in a Chicago hospital.

Tirthankar Chakraborty headshot

Wall Street to Get Its Mojo Back: Here're the Big Winners

by Tirthankar Chakraborty

Thanks to Trump's plans to reopen U.S. states to Gilead's coronavirus treatment, investors pin hopes on a Wall Street recovery. And with the broader market poised to gain, it seems prudent to pick stocks with solid prospects.

Sanghamitra Saha headshot

Optimism Back in Wall Street? ETFs Areas to Win the Most

by Sanghamitra Saha

Wall Street is likely to stage a relief rally on hopes of reopening of American businesses, improving virus outlook and chances of treatment coming on stream.

Ritujay Ghosh headshot

Gilead Brings Likely Coronavirus Cure, Pharma Rallies on R&D

by Ritujay Ghosh

Shares of Gilead Science Inc. (GILD) rally on media reports that severe coronavirus patients were responding positively to the company's experimental treatment, remdesivir.

Gilead Down on Suspension of Coronavirus Study in China

by Zacks Equity Research

Gilead (GILD) declines after a study on investigational antiviral, remdesivir, was suspended in China due to the lack of eligible patients.

The Zacks Analyst Blog Highlights: Pluristem Therapeutics, Mesoblast, Gilead Sciences, Pfizer and Regeneron

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Pluristem Therapeutics, Mesoblast, Gilead Sciences, Pfizer and Regeneron

Sweta Jaiswal, FRM headshot

ETFs to Rise as Gilead Drug Shows Promise in Coronavirus Cure

by Sweta Jaiswal, FRM

Gilead Sciences (GILD) has ignited a ray of hope with its recently-released positive data on the role of remdesivir as a COVID-19 treatment.